SCHEMBL12863898

SCHEMBL12863898

CCC(OC(=O)c1cc2occc2[nH]1)C(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DAO P14920 2/20 0.51
▸ KDM4E B2RXH2 6/20 0.40
▸ LMNA P02545 3/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ POLB P06746 1/20 0.38
▸ GAA P10253 2/20 0.38
▸ ALDH1A1 P00352 5/20 0.36
▸ HPGD P15428 4/20 0.36
▸ HSD17B10 Q99714 3/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ RAB9A P51151 3/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ GABRA1 P14867 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12879946 0.87 DAO (0.54) DAOKDM4ELMNAL3MBTL1TP53
SCHEMBL12864275 0.85 DAO (0.55) DAOKDM4ELMNAL3MBTL1TP53
SCHEMBL12864274 0.84 DAO (0.56) DAOKDM4ELMNAL3MBTL1TP53
SCHEMBL12863896 0.84 DAO (0.56) DAOKDM4ELMNAL3MBTL1TP53
SCHEMBL12863886 0.84 DAO (0.56) DAOKDM4ELMNAL3MBTL1TP53
SCHEMBL12864273 0.84 DAO (0.59) DAOKDM4ELMNAL3MBTL1TP53
SCHEMBL1171473 0.84 DAO (0.59) DAOKDM4ELMNAL3MBTL1TP53
SCHEMBL12903514 0.82 DAO (0.58) DAOKDM4ELMNAL3MBTL1TP53
SCHEMBL1170866 0.81 DAO (0.48) DAOKDM4ELMNAL3MBTL1TP53
SCHEMBL12864259 0.81 DAO (0.48) DAOKDM4ELMNAL3MBTL1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034434-A1 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2011-02-10 — — US disclosed
US-20110034434-A1 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2011-02-10 — — US disclosed
US-20100120740-A1 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2010-05-13 — — US disclosed
US-20100120740-A1 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2010-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120740-A1 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE DDO, DAO, AOC1 DAO 2/4885KDM4E 2574/4885LMNA 4705/4885
US-20110034434-A1 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE DDO, DAO, AOC1 DAO 2/4885KDM4E 2574/4885LMNA 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback